Better
Treatments,
More Tomorrows
Better
Treatments,
More Tomorrows
We Are
Advancing
a growing pipeline of product candidates for the treatment of highly resistant cancers and viruses.
Innovative
Therapies
through the use of proprietary technologies and data to develop a next generation anthracycline, immune/transcription modulators (STAT3 inhibitors) and metabolism/glycosylation inhibitors.
Innovative
Therapies
through the use of proprietary technologies and data to develop a next generation anthracycline, immune/transcription modulators (STAT3 inhibitors) and metabolism/glycosylation inhibitors.
Priority Development Pipeline
Latest Releases
Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update
- Positive advancements, encouraging preclinical and clinical data, and development activity in...
Moleculin Receives Approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
- Dosing for first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 in...
Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
- Preliminary positive safety and efficacy data from second Phase 1 AML study validate advancement...
Stock Information
NASDAQ: MBRX
NASDAQ: MBRX
Corporate
Presentation
Corporate
Presentation